Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of oral BEZ235 in advanced endometrial carcinoma (second-line)
2010-024396-12Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in endometrial cancer (EC), sponsored by Novartis. Primary endpoint: Overall Response Rate (ORR) per RECIST in PI3K pathway-activated patients. Started Mar 2011; status: terminated.
02
Drugs
dactolisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2010-024396-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024396-12.